Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-all treated according to the NOPHO ALL-1992 and ALL-2000 protocols

Pediatric Blood and Cancer

Volumn 61, Issue 3, 2014, Pages 424-430

  Fogelstrand, Linda ^a   Staffas, Anna ^a   Wasslavik, Carina ^a   Sjögren, Helene ^a   Söderhäll, Stefan ^b   Frost, Britt Marie ^c   Forestier, Erik ^d   Degerman, Sofie ^d   Behrendtz, Mikael ^e   Heldrup, Jesper ^f   Karrman, Kristina ^g   Johansson, Bertil ^g   Heyman, Mats ^h   Abrahamsson, Jonas ⁱ   Palmqvist, Lars ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Department of Women's and Children's Health   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cytogenetics and molecular genetics; FBXW7; NOTCH1; Pediatric acute lymphoblastic leukemia; Prognosis

Indexed keywords

FBXW7 PROTEIN; MYC PROTEIN; NOTCH1 RECEPTOR; PROTEIN MYB; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; ONCOGENE MYC; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; WILD TYPE; YOUNG ADULT;

CYTOGENETICS AND MOLECULAR GENETICS; FBXW7; NOTCH1; PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA; PROGNOSIS;

ADOLESCENT; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; F-BOX PROTEINS; FEMALE; GENES, MYB; HOMEODOMAIN PROTEINS; HUMANS; INFANT; MALE; MUTATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECEPTOR, NOTCH1; UBIQUITIN-PROTEIN LIGASES;

EID: 84892515823     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24803     Document Type: Article

References (39)

1. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2009; 24:345-354.
2. Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118:2077-2084.
3. Willemse MJ, Seriu T, Hettinger K, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99:4386-4393.
4. Thorn I, Forestier E, Botling J, et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: A swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol 2011; 152:743-753.
5. Karrman K, Forestier E, Heyman M, et al. Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: Rare T-cell receptor gene rearrangements are associated with poor outcome. Genes Chromosomes Cancer 2009; 48:795-805.
6. Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of NOTCH1. Immunity 1999; 10:547-558.
7. Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999; 11:299-308.
8. Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996; 183:2283-2291.
9. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of Notch1 in human t cell acute lymphoblastic leukemia. Science 2004; 306:269-271.
10. Breit S, Stanulla M, Flohr T, et al. Activating Notch1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006; 108:1151-1157.
11. Mansur MB, Hassan R, Barbosa TC, et al. Impact of complex Notch1 mutations on survival in paediatric T-cell leukaemia. BMC cancer 2012; 12:9.
12. Zhu YM, Zhao WL, Fu JF, et al. Notch1 mutations in T-cell acute lymphoblastic leukemia: Prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 2006; 12:3043-3049.
13. O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate notch pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204:1813-1824.
14. Malyukova A, Dohda T, von der Lehr N, et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67:5611-5616.
15. Song JH, Schnittke N, Zaat A, et al. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res 2008; 32:1751-1755.
16. Zuurbier L, Homminga I, Calvert V, et al. Notch1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 2010; 24:2014-2022.
17. Clappier E, Collette S, Grardel N, et al. Notch1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on eortc trials 58881 and 58951. Leukemia 2010; 24:2023-2031.
18. Ma J, Wu M. The indicative effect of Notch1 expression for the prognosis of T-cell acute lymphocytic leukemia: A systematic review. Mol Biol Rep 2012; 39:6095-6100.
19. Jenkinson S, Koo K, Mansour MR, et al. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia 2013; 27:41-47.
20. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9:1783-1786.
21. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion. Hum Mutat 2000; 15:7-12.
22. Bamford S, Dawson E, Forbes S, et al. The cosmic (catalogue of somatic mutations in cancer) database and website. Br J Cancer 2004; 91:355-358.
23. Staffas A, Kanduri M, Hovland R, et al. Presence of FLT3-ITD and high baalc expression are independent prognostic markers in childhood acute myeloid leukemia. Blood 2011; 118:5905-5913.
24. Park MJ, Taki T, Oda M, et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-hodgkin lymphoma. Br J Haematol 2009; 145:198-206.
25. Clappier E, Cuccuini W, Kalota A, et al. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 2007; 110:1251-1261.
26. Erbilgin Y, Sayitoglu M, Hatirnaz O, et al. Prognostic significance of NOTCH1 and FBXW7 mutations in pediatric T-ALL. Dis Markers 2010; 28:353-360.
27. Larson Gedman A, Chen Q, Kugel Desmoulin S, et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: A report from the Children's Oncology Group. Leukemia 2009; 23:1417-1425.
28. van Grotel M, Meijerink JP, van Wering ER, et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008; 22:124-131.
29. Ben Abdelali R, Asnafi V, Leguay T, et al. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: A GRAALL study. Blood 2011; 118:5099-5107.
30. Callens C, Baleydier F, Lengline E, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, flash deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol 2012; 30:1966-1973.
31. Kox C, Zimmermann M, Stanulla M, et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010; 24:2005-2013.
32. Sharma VM, Calvo JA, Draheim KM, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol 2006; 26:8022-8031.
33. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006; 20:2096-2109.
34. Reedijk M, Odorcic S, Zhang H, et al. Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol 2008; 33:1223-1229.
35. Silva A, Jotta PY, Silveira AB, et al. Regulation of PTEN by CK2 and notch1 in primary T-cell acute lymphoblastic leukemia: Rationale for combined use of CK2- and gamma-secretase inhibitors. Haematologica 2010; 95:674-678.
36. Schwarzer R, Dorken B, Jundt F. Notch is an essential upstream regulator of NF-kappab and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012; 26:806-813.
37. Suhasini M, Pilz RB. Transcriptional elongation of c-myb is regulated by NF-kappab (p50/ReIB). Oncogene 1999; 18:7360-7369.
38. Naito T, Tanaka H, Naoe Y, et al. Transcriptional control of T-cell development. Int Immunol 2011; 23:661-668.
39. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 2007; 39:593-595.